Detailed clinical research summaries for the GLP-1 trial program. Each page distills a major trial — STEP, SURMOUNT, SELECT, FLOW — and its clinical implications.
STEP trials (semaglutide)
STEP-1, STEP-4, STEP-HFpEF. Weight management foundation.
SURMOUNT trials (tirzepatide)
SURMOUNT-1, SURMOUNT-OSA. Tirzepatide foundation + OSA approval.
SELECT — CV outcomes
20% MACE reduction in obesity + CVD without diabetes.
FLOW — kidney outcomes
24% reduction in major kidney events in T2D + CKD.
Mechanism of GLP-1
Pharmacology beyond "appetite suppressant."
Contraindications
MTC, MEN-2, pregnancy, severe GI disease.
Drug interactions
Insulin, anesthesia, oral contraceptives, pregnancy planning.